Met (M1268T), active

N-terminal 6His-tagged recombinant, human Met amino acids 974-end, containing the mutation M1268T. Met M1268T is a somatic mutation that has been identified in patients with papillary renal carcinomas (HPRC). In vitro studies have demonstrated enhanced kinase activity from this mutant.

Catalog #: 14-817


Biological Information
Background Information:
MET tyrosine kinase is a high-affinity receptor for hepatocyte growth factor/scatter factor. Signaling via this receptor-ligand pair has been shown to affect a wide range of biological activities, including angiogenesis, cellular motility, growth, invasion, and morphogenic differentiation. Mutations in the MET tyrosine kinase receptor have been identified in both hereditary and sporadic forms of papillary renal carcinoma and implicated in tumor growth, invasion, and metastasis. GenBank J02958. The recombinant protein contains the amino acid substitutions A1209G and V1290L with reference to GenBank J02958. Both substitutions are reported in GenBank BU595386, BQ315895 and BQ316491.
Target Class:
Receptor Tyrosine Kinase (RTK): Type X RTK: HGF Receptor Family
Accession Number:
Refer to CoA for Accession Number
Target Name:
Target Aliases:
Hepatocyte growth factor receptor, HGFR, tyrosine-protein kinase Met, MET, AUTS9, c-Met, RCCP2, HGFR
Target Species:
Product Type:
Drug Discovery & Development
Storage Conditions:
6 months at -70°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit for a list of products that are governed by limited use label license terms and relevant patent and trademark information.


14-817x Datasheet

View Document